Holen Sie sich die Stockscreener-App
7.40
0.00%
0.00
Handel nachbörslich:
7.40
Schlusskurs vom Vortag:
$7.40
Offen:
$7.38
24-Stunden-Volumen:
123.21K
Relative Volume:
2.18
Marktkapitalisierung:
$54.55M
Einnahmen:
$7.00M
Nettoeinkommen (Verlust:
$-56.03M
KGV:
-0.9662
EPS:
-7.6589
Netto-Cashflow:
$-51.79M
1W Leistung:
-0.67%
1M Leistung:
+6.63%
6M Leistung:
+88.30%
1J Leistung:
+79.61%
1-Tages-Spanne:
$7.36
$7.45
1-Wochen-Bereich:
$7.35
$7.55
52-Wochen-Spanne:
$3.5334
$7.55
Kezar Life Sciences Inc Stock (KZR) Company Profile
Firmenname
Kezar Life Sciences Inc
Sektor
Branche
Telefon
650-822-5600
Adresse
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
7.40 | 54.55M | 7.00M | -56.03M | -51.79M | -7.6589 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-17 | Herabstufung | Jefferies | Buy → Hold |
| 2025-10-17 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-08-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Wells Fargo | Outperform |
| 2018-07-16 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Kezar Life Sciences Inc Aktie (KZR) Neueste Nachrichten
Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Volatility Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - MSN
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Kezar Life Sciences Announces Lease Termination and Executive Separation Agreements in April 2026 - Minichart
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart
KZR PE Ratio & Valuation, Is KZR Overvalued - Intellectia AI
Kezar Life Sciences announces lease termination and executive departures following merger agreement - Investing.com Canada
Kezar Life Sciences Announces Major Executive Leadership Changes - TipRanks
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline - TipRanks
Aurinia (NASDAQ: AUPH) to acquire Kezar with $6.955 per share cash and CVRs - stocktitan.net
Kezar Life Sciences' Christopher J. Kirk, Marc L. Belsky and Mark Schiller to Depart under Separation Agreements - TradingView
Aurinia to acquire Kezar (NASDAQ: KZR) for $6.955 cash plus CVR - stocktitan.net
KZR Technical Analysis & Stock Price Forecast - Intellectia AI
Major Kezar (KZR) shareholder signs merger support pact and drops bid - stocktitan.net
Aurinia Pharmaceuticals: $6.955 Per Share Acquisition Of Kezar Life Sciences To Expand Autoimmune Pipeline - Pulse 2.0
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Zenopa
Trend Recap: What is Kezar Life Sciences Incs market position2026 Chart Watch & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Aurinia to acquire Kezar Life Sciences - The Pharma Letter
Are KZR, NSA, EQH, CTRA Obtaining Fair Deals for their Shareholders? - Sahm
KZR Acquisition by Aurinia Pharmaceuticals Valued at $6.955 per Share - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Cash Deal - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Strategic Deal - GuruFocus
Jefferies maintains Kezar Life Sciences stock rating on acquisition By Investing.com - Investing.com India
Jefferies maintains Kezar Life Sciences stock rating on acquisition - Investing.com
After failed takeover bid, activist investor finds new way to buy out Bay Area company - The Business Journals
Aurinia Pharma U.S., Inc. agreed to acquire Kezar Life Sciences, Inc. for $51 million. - marketscreener.com
Shareholder Alert: The Ademi Firm investigates whether Kezar Lif - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) - Morningstar
US Market Wrap: Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Aurinia to acquire Kezar Life Sciences for $6.955 per share By Investing.com - Investing.com South Africa
Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
Aurinia Pharmaceuticals Acquires Kezar Life Sciences - Contract Pharma
Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal - TipRanks
Kezar Life Sciences stock jumps on Aurinia acquisition deal By Investing.com - Investing.com Australia
Kezar Life Sciences stock jumps on Aurinia acquisition deal - Investing.com
Kezar Life Sciences to Be Acquired by Aurinia in $6.955-Per-Share Cash Tender Offer Plus CVR - TradingView
Aurinia (NASDAQ: AUPH) to buy Kezar (NASDAQ: KZR) for $6.955 plus CVR - stocktitan.net
KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe
Aurinia to acquire Kezar Life Sciences for $6.955 per share - Investing.com
What is the next catalyst for Kezar Life Sciences Inc2026 Earnings Impact & Fast Moving Market Watchlists - baoquankhu1.vn
Kezar Life Sciences 2025 Annual Report: Strategic Alternatives, Clinical Pipeline, and Key Risks - Minichart
KZR: Net loss narrowed to $56M in 2025 as restructuring and strategic review efforts continued - TradingView
[10-K] Kezar Life Sciences, Inc. Files Annual Report - Stock Titan
Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Kezar Life Sciences (KZR) to Release Earnings on Tuesday - Defense World
Highs Report: Can Kezar Life Sciences Inc maintain its current growth rate2026 Key Highlights & Weekly Breakout Watchlists - baoquankhu1.vn
If You Invested $1,000 in Kezar Life Sciences (KZR) - stocktitan.net
Finanzdaten der Kezar Life Sciences Inc-Aktie (KZR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kezar Life Sciences Inc-Aktie (KZR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schiller Mark C. | Chief Operating Officer |
Jul 02 '25 |
Sale |
4.28 |
561 |
2,401 |
2,739 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):